{"disease":{"id":"breast-cancer-estrogen-receptor-positive","name":"breast cancer estrogen receptor positive"},"drugs":{"marketed":[{"drug_id":"palbociclib-in-combination-with-ai","indication_name":"Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HER2-negative) advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women with estrogen receptor-positive (ER+), HER2-negative breast cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Palbociclib in combination with AI","generic_name":"palbociclib-in-combination-with-ai","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CDK4/6","drug_class":"CDK inhibitor","quality_score":50,"revenue":"4122","mechanism":""},{"drug_id":"novel-hormonal-therapy","indication_name":"Advanced or metastatic breast cancer in postmenopausal women with one or more estrogen receptors and/or progesterone receptors and a HER2-positive tumor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novel hormonal therapy","generic_name":"novel-hormonal-therapy","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"hormone receptors, EGFR","drug_class":"hormonal therapy","quality_score":45,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04601116","title":"The MASTER Study (MAmmary Cancer STatin ER Positive Study)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":3360,"lead_sponsor_name":"Aarhus University Hospital","has_results":false},{"nct_id":"NCT07391774","title":"Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":1978,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03503799","title":"Reaching for Evidence-baSed Chemotherapy Use in Endocrine Sensitive Breast Cancer","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1191,"lead_sponsor_name":"North Eastern German Society of Gynaecological Oncology","has_results":false},{"nct_id":"NCT06671912","title":"Testing Low Dose Tamoxifen for Invasive Breast Cancer, the (LoTam) Trial","phase":"PHASE3","overall_status":"SUSPENDED","enrollment_count":1156,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false},{"nct_id":"NCT03723928","title":"S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":739,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":false},{"nct_id":"NCT07340541","title":"Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":700,"lead_sponsor_name":"UNC Lineberger Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT02947685","title":"Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":518,"lead_sponsor_name":"Alliance Foundation Trials, LLC.","has_results":true},{"nct_id":"NCT07136493","title":"Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With Early-Stage Breast Cancer","phase":"NA","overall_status":"SUSPENDED","enrollment_count":350,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT04086875","title":"A Text-based Intervention in Improving Adherence to Hormone Therapy in Patients With Stage I-III Hormone Receptor Positive Breast Cancer","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":332,"lead_sponsor_name":"Thomas Jefferson University","has_results":false},{"nct_id":"NCT04571437","title":"Letrozole and Metronomic Capecitabine in ER-positive HER2 Negative Advanced Breast Cancer (B-001 Study)","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":204,"lead_sponsor_name":"Cairo University","has_results":false},{"nct_id":"NCT02202746","title":"A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":178,"lead_sponsor_name":"Clovis Oncology, Inc.","has_results":true},{"nct_id":"NCT03250676","title":"Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":151,"lead_sponsor_name":"Eisai Inc.","has_results":true},{"nct_id":"NCT06474988","title":"Characterization of Biophysical and Mechanical Parameters on Skin of Breast Cancer Patients","phase":"","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"European Institute of Oncology","has_results":false},{"nct_id":"NCT03644186","title":"To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":147,"lead_sponsor_name":"ETOP IBCSG Partners Foundation","has_results":true},{"nct_id":"NCT07499999","title":"Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":140,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT00676663","title":"Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":130,"lead_sponsor_name":"Syndax Pharmaceuticals","has_results":true},{"nct_id":"NCT05868226","title":"PRE-I-SPY Phase I/Ib Oncology Platform Program","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":124,"lead_sponsor_name":"QuantumLeap Healthcare Collaborative","has_results":false},{"nct_id":"NCT06623903","title":"Early Changes in Metabolic Health in Breast Cancer Patients Initiating Endocrine Therapy","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":112,"lead_sponsor_name":"Aarhus University Hospital","has_results":false},{"nct_id":"NCT03750396","title":"Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":110,"lead_sponsor_name":"Gangnam Severance Hospital","has_results":false},{"nct_id":"NCT04504916","title":"A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":102,"lead_sponsor_name":"VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":true},{"nct_id":"NCT04597580","title":"Personalised Disease Monitoring in Metastatic Breast Cancer","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":97,"lead_sponsor_name":"The Christie NHS Foundation Trust","has_results":false},{"nct_id":"NCT03106077","title":"Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":96,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT03886389","title":"Breast Cancer Diet Intervention Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"Helse Stavanger HF","has_results":false},{"nct_id":"NCT06439693","title":"The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":72,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT03395899","title":"Pre-operative Immunotherapy Combination Strategies in Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":71,"lead_sponsor_name":"Queen Mary University of London","has_results":false},{"nct_id":"NCT03719495","title":"Evaluation of Endocrine Therapy Effects of Host Immunity in Early Stage Breast Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":68,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT03285568","title":"Patterns of Prescribing and Monitoring of Palbociclib","phase":"","overall_status":"COMPLETED","enrollment_count":67,"lead_sponsor_name":"Rush University Medical Center","has_results":false},{"nct_id":"NCT02820961","title":"Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":61,"lead_sponsor_name":"Syndax Pharmaceuticals","has_results":false},{"nct_id":"NCT02997995","title":"Durvalumab and Endocrine Therapy in ER+/Her2- Breast Cancer After CD8+ Infiltration Effective Immune-Attractant Exposure","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":61,"lead_sponsor_name":"UNICANCER","has_results":false},{"nct_id":"NCT00338728","title":"Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":59,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT06008158","title":"Evaluation of a Once Per Day Regimen of Accelerated Partial Breast Irradiation for Improved Breast Appearance in Pts w/Low Risk, Hormone Responsive Brst Ca","phase":"PHASE2","overall_status":"SUSPENDED","enrollment_count":48,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT02957968","title":"Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":46,"lead_sponsor_name":"Virginia Commonwealth University","has_results":true},{"nct_id":"NCT07191717","title":"Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":42,"lead_sponsor_name":"Jonsson Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT06538389","title":"High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer","phase":"PHASE2","overall_status":"SUSPENDED","enrollment_count":36,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT03691493","title":"Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Emory University","has_results":true},{"nct_id":"NCT06525766","title":"Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":35,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03725436","title":"ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":28,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06401889","title":"Enhancing Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor Therapy","phase":"","overall_status":"RECRUITING","enrollment_count":25,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06733233","title":"A Study Evaluating the Efficacy and Safety of De Trastuzumab (T-DXd) in Combination with Immunotherapy for the Neoadjuvant Treatment of HR-positive HER2 Low-expressing Chinese Patients with Early-stage Breast Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":23,"lead_sponsor_name":"Guangzhou Women and Children's Medical Center","has_results":false},{"nct_id":"NCT06343987","title":"The FEMA Study: Feasibility of Exercise in Patients With Metastatic Breast Cancer and Adiposity","phase":"NA","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"Aarhus University Hospital","has_results":false},{"nct_id":"NCT03554044","title":"T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT03523195","title":"Exercise Intervention After Cancer Treatment for Improving Health in Stage II-III Breast Cancer Survivors","phase":"NA","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT06260033","title":"Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT03132467","title":"Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT03566485","title":"Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":12,"lead_sponsor_name":"Vanderbilt-Ingram Cancer Center","has_results":true},{"nct_id":"NCT06006910","title":"Electronic Medical Record-Based Nudge to Reduce SLNB","phase":"","overall_status":"COMPLETED","enrollment_count":7,"lead_sponsor_name":"University of Pittsburgh Medical Center","has_results":false},{"nct_id":"NCT03715959","title":"Nipple Aspirate Fluid in Detecting Breast Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":2,"lead_sponsor_name":"Ohio State University Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT04965688","title":"Biology Guided Therapy for Breast Cancer for ER Positive","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"Inova Health Care Services","has_results":true},{"nct_id":"NCT04602117","title":"ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"QuantumLeap Healthcare Collaborative","has_results":false},{"nct_id":"NCT03666819","title":"Carbon Dioxide Fractional Laser in Treating Participants With Stage 0-III Hormone Receptor-Positive Breast Cancer With Vulvovaginal Atrophy","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Mayo Clinic","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}